Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
Among patients with advanced nonsquamous NSCLC that had progressed during or after platinum-based chemotherapy, overall survival was longer with nivolumab than with docetaxel. (...